One of the first descriptions of a “pulmonary plus pressure machine” in 1936 describes varying success in the treatment of cardiac asthma and bronchial asthma. The author describes how an Electrolux or Hoover vacuum cleaner can be used to supply air at positive pressure and wisely cautions that “the machine should be run for some minutes first of all to get rid of the dust”.

The aim of this article is to review the effects of non-invasive ventilation in acute respiratory failure, the evidence for its use in an emergency setting, and make some recommendations concerning its optimal use.

**Pathophysiological effects of non-invasive ventilation**

**EFFECTS ON THE RESPIRATORY SYSTEM**

Extrinsically applied positive end expiratory pressure (ePEEP) increases alveolar size and recruitment. This expands the area available for gas exchange, reduces intrapulmonary shunt, improves lung compliance, and decreases the work of breathing. It acts to negate the effects of intrinsic PEEP (iPEEP), which is the cause of dynamic airway compression and gas trapping. Ventilation is improved with beneficial effects on the alveolar-arterial gradient, hypercarbia and, to a lesser extent, hypoxia. Pressure support (alone or as part of bilevel positive airway pressure, BiPAP) further augments alveolar ventilation and allows some respiratory muscle rest during the inspiratory phase.

**EFFECTS ON THE CARDIOVASCULAR SYSTEM**

PEEP reduces venous return to the right side of the heart. Left ventricular preload, transmural pressure, and relative afterload are all decreased without altering myocardial contractility. Thus, the ejection fraction improves without an increase in myocardial oxygen consumption. It appears that those with worst ventricular dysfunction show the most significant improvement in stroke volume index with continuous positive airway pressure (CPAP).

Overall, CPAP leads to a decrease in arterial pressure, heart rate, and rate-pressure product within 10 minutes, without exacerbation of hypotension.

**EFFECTS ON OTHER SYSTEMS**

*Intracranial pressure (ICP)*—in patients with raised ICP there may be an increase in ICP by at least the same degree as the PEEP applied. PEEP causes decreased sodium excretion and urine output, possibly due to raised vena caval pressure reducing cortical blood flow.

**Applying non-invasive ventilation**

**EQUIPMENT**

There are two major options for interface between patient and machine: nasal masks and (oronasal) facemasks. Nasal masks have traditionally been used in the setting of chronic, home therapy and have also been applied to the acute setting. They offer the advantages of a smaller dead space, less claustrophobia, and the ability to utilise the mouth quickly and easily (for communication, expectoration, vomiting, and oral intake), albeit with the loss of pressure. Dyspnoeic patients, however, are typically mouth breathers and the oral route offers less resistance to gas flow. Thus, facemasks are preferable for treatment of acute respiratory failure in the emergency department.

The use of a mouthpiece has also been described but requires nasal occlusion and a good mouth seal making leak avoidance difficult. A full facemask has recently been developed and is reported as having advantages over other means of applying non-invasive ventilation.

**MONITORING**

Monitoring of patients undergoing non-invasive ventilation should be similar to that generally used to manage patients with acute respiratory failure. Non-invasive blood pressure monitoring at intervals of 5–15 minutes, continuous electrocardiography (ECG) monitoring, ongoing pulse oximetry, assessment of respiratory rate, temperature, chest radiography, and 12 lead ECG is recommended.

Frequent arterial blood gas analysis will aid therapeutic decision making but will be limited by the means of arterial sampling employed (intermittent puncture compared with arterial line). The frequency of blood gas analysis in the major trials was quite variable; from every 30 minutes for six hours to at one hour, three days, and seven days. Blood gas analysis as
### Table 1: Non-invasive ventilation randomised controlled trials for COAD

<table>
<thead>
<tr>
<th>Trial</th>
<th>No of subjects</th>
<th>Type of ventilation and location</th>
<th>Duration of ventilation</th>
<th>Major outcomes</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kraemer et al.</td>
<td>29</td>
<td>Total Nasal BiPAP</td>
<td>14.4 (2.2) hours/day</td>
<td>73% intubation rate overall</td>
<td>Non-invasive ventilation decreased the intubation rate, particularly in COAD subgroup</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>67% for COAD subgroup</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>COAD 3.8 (1.4) days</td>
<td>Improved HR, RR at 1 hour and PaO2 at 1–6 hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9%</td>
<td>Improved some clinical parameters</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>29%</td>
<td>Better PaO2 at 6 hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Face PSV</td>
<td>6 hours/day</td>
<td>26% failure rate. 33% failure rate for BiPAP</td>
<td>Non-invasive ventilation sped improvement and decreased both intubation rate and length of stay. Improved some clinical parameters</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11.7 (3.5) days length of stay</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30% 30 day mortality (efficacy)</td>
<td>Non-invasive ventilation decreased mortality and improved some clinical parameters</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.0 (2–9) days</td>
<td>Not significant on an intention-to-treat basis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Evidence for the use of non-invasive ventilation

**EVIDENCE FOR USE IN OBSTRUCTIVE AIRWAYS DISEASE**

There are only four randomised controlled trials comparing non-invasive ventilation with standard treatment in acute exacerbations of obstructive airways disease carried out in intensive care units (Table 1). Different modes of ventilation were used in each: nasal BIPAP, facemask pressure support ventilation (no CPAP/EPAP component), facemask BiPAP, and nasal volume cycled positive pressure ventilation.

Two of the studies using pressure cycled ventilation demonstrated significantly decreased intubation rates compared with standard treatment (11/43 (26%) vs 11/14 (79%) and 11/43 (26%) vs 11/43 (74%), respectively). The other study using pressure cycled ventilation found BiPAP to be successful (defined as improvement in gas exchange, clinical parameters, and discharge from the hospital) in 14/15 (93%) compared with 9/15 (60%) with standard treatment alone. Those who failed with standard treatment received a trial of BiPAP that was successful in 4/6 (60%). All the studies using pressure cycled ventilation showed significant differences in some respiratory and cardiovascular parameters (respiratory rate, heart rate, pH, and PaO2) after one and six hours of treatment, compared with standard treatment. There was no significant improvement in arterial carbon dioxide tension (PaCO2) compared with standard treatment. On subsequent days there was no difference in these parameters between treatment and control.

### Level of PEEP

The goals of acute respiratory therapy should be maintenance of an arterial oxygen saturation >90% or arterial oxygen tension (PaO2) >8.0 kPa (>60 mm Hg). This degree of oxygenation should be maintained during weaning from non-invasive ventilation. The optimal level of PEEP to apply is one which closely matches iPEEP. Given the difficulty in measuring iPEEP in the emergency setting the most practical solution is a gradual increase in ePEEP (for example by 2.5–5.0 cm H2O) until a satisfactory response is achieved. It is recommended that PEEP (that is CPAP or expiratory positive airway pressure, EPAP) be started at 4–6 cm H2O and inspiratory pressure (if used) at 8–14 cm H2O. The effect of changes in non-invasive ventilation on arterial blood gases is evident within 10–15 minutes with no further effect demonstrable at 30 minutes. This suggests incremental increases in ventilatory therapy could be applied every 15 minutes, if needed, until a satisfactory degree of oxygenation is attained. The clinician should also observe an improvement in the clinical condition within one to two hours.

---

*Statistically significant results only: p < 0.05; comparison: intervention vs standard therapy. APO = acute pulmonary oedema; BiPAP = bilevel positive airway pressure; COAD = chronic obstructive airways disease; HR = heart rate; PaO2 = arterial oxygen tension; PSV = pressure support ventilation; RR = respiratory rate.*
Table 2: Non-invasive ventilation randomised controlled trials for APO

<table>
<thead>
<tr>
<th>Study</th>
<th>No of subjects</th>
<th>Duration</th>
<th>Major outcomes</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Räsänen et al</td>
<td>28</td>
<td>40 hours</td>
<td>CPAP improved gas exchange, decreased respiratory work, circulatory stress, and may decrease need for a traditional ventilator.</td>
<td>CPAP improved respiratory work, decreased need for a traditional ventilator.</td>
</tr>
<tr>
<td>Lin et al</td>
<td>57</td>
<td>24 hours</td>
<td>BiPAP better than CPAP in APO but associated with higher number of intubations.</td>
<td>BiPAP resulted in physiological improvement and decreased need for intubation in intensive care unit.</td>
</tr>
<tr>
<td>Wood et al</td>
<td>27</td>
<td>100 hours</td>
<td>Non-invasive ventilation may delay endotracheal intubation and is associated with increased hospital mortality.</td>
<td>No significant difference in intubation rate.</td>
</tr>
</tbody>
</table>

Table 2: Evidence for use in acute pulmonary oedema

There are four randomised controlled trials investigating non-invasive ventilation in acute pulmonary oedema (table 2). Three compare CPAP with standard treatment with high flow oxygen in intensive care settings and one compares BiPAP with CPAP for emergency department treatment of pulmonary oedema. These studies indicate that non-invasive ventilation is beneficial to the acute treatment of chronic obstructive airways disease; it reduces the need for intubation and may reduce both hospital length of stay and mortality. Acidosis and hypoxia are more responsive to treatment than hypercapnia and show significant improvement within one hour of treatment.
0%–30%) with CPAP, compared with 31/90 (34%, range 24%–60%) with standard treatment but this was not statistically significant in one.28 No complications of non-invasive ventilatory therapy were reported.

Medium to long term outcomes were no different in any of the studies comparing CPAP with standard treatment. Bersten et al demonstrated no significant differences in blood gas analysis at 24 hours.73 Hospital mortality and length of stay was not significantly different in any of the studies. There was no difference in one year mortality.25

The one study comparing CPAP with BiPAP suggested more rapid improvement with BiPAP.4 Patients receiving BiPAP had statistically significant improvements in PaCO₂, pH, heart rate, respiratory rate, and dyspnoea scores at 30 minutes but CPAP showed only improvements in respiratory rate. This study was terminated early, with only 27 patients, because of a significantly higher incidence of myocardial infarction in patients receiving BiPAP: 10/14 (71%) compared with 4/13 (31%) with CPAP and 38% in a matched historical control group of 200. There were no statistically significant differences in baseline characteristics of the two study groups. Whether BiPAP caused the infarcts is unclear. Analysis of creatine kinase MB fractions suggests that a significant number of the infarctions may have been underway at enrolment. There was no significant difference in time on the device, mortality, or length of stay (intensive care unit and hospital) between the groups.

When BiPAP and standard treatment was compared with standard treatment alone in a heterogeneous group of emergency department patients27 (10 with acute pulmonary oedema, six chronic obstructive airways disease, nine pneumonia, one interstitial lung disease, and one sepsis) a trend towards increased hospital mortality (4/16 (25%) compared with 0/11) and number of acquired organ system derangements was found in the group randomised to BiPAP. Those receiving BiPAP tended to improve their mean arterial pressure and PaO₂ faster than the control group. The authors suggest that the poorer outcome may be related to predetermined biases on the part of treating physicians and respiratory therapists in favour of non-invasive ventilation (a reluctance to abandon non-invasive ventilation until the last moment). As noted by the authors, the risk of both type one and two errors is increased in a study of this size. Although there was no statistically significant difference between the groups, a higher number of patients in the treatment group had pneumonia at presentation, 7/16 or 43.8% compared with 2/11 or 18.2% of those receiving standard treatment. It is not stated what the presenting diagnosis of the hospital non-survivors was but pneumonia has been associated with poorer outcome in patients receiving non-invasive ventilation.45 52

Case series studies also support the beneficial effect of BiPAP40 45 47 56–61 and CPAP15 62–64 on pulmonary oedema. The largest of the studies looking at CPAP on acute pulmonary oedema was a retrospective review of 75 patients treated in the emergency department in whom only 4% required intubation and mean time on CPAP was 1.9 hours.44

Overall, the above studies indicate that non-invasive ventilation was effective in decreasing the intubation rate in acute pulmonary oedema and speeds the acute treatment of pulmonary oedema with few complications.43 There is no significant improvement in length of stay or long term mortality compared with standard treatment.

EVIDENCE FOR USE IN OTHER RESPIRATORY DISORDERS

Non-invasive ventilation is widely used in non-acute settings such as home treatment of stable chronic obstructive airways disease,60 61 postoperatively,68 69 and in weaning from conventional mechanical ventilation.70

Case reports and small case series describe the use of non-invasive ventilation for acute respiratory failure of many aetiologies other than cardiogenic pulmonary oedema and obstructive airways disease. These include pneumonia,45 52 59 69 pulmonary embolism,42 stroke,50 overdose,59 restrictive lung diseases,60 71 72 acute respiratory distress syndrome of various aetiologies,45 71 72 Pneumocystis carinii pneumonia,47 Goodpasture’s disease,76 fat embolism,77 bronchiectasis,77 mediastinitis,78 laryngeal dyspnoea,60 and as an option to traditional ventilation in palliative care.79

PROBLEMS WITH NON-INVASIVE VENTILATION

Non-invasive ventilation appears to be remarkably free of serious complications and side effects. The primary disadvantage of non-invasive ventilation is its reliance on a spontaneously breathing patient who is able to protect their airway against the risk of aspiration. If either of these conditions are not met, endotracheal intubation and traditional ventilation is indicated.

The most commonly reported complications of non-invasive ventilation are nasal bridge skin abrasions25 51 52 56 61 74 75 80 and patient intolerance of the treatment.28 52 54 75 80 Although a possibility with firmly applied masks, skin abrasions are usually only seen in long term use of non-invasive ventilation. Patient intolerance of non-invasive ventilation can be reduced by education before its application (although this is often difficult in an emergency setting) and ongoing explanation and reassurance. Hypoxic and hypercarbic effects on mental state may be in part responsible for this intolerance.

Gastric distension and aspiration is a frequently discussed side effect of non-invasive ventilation, but is relatively rarely described in clinical trials.45 81 82 Studies of the pressure needed to inflate the stomach via non-invasive ventilation suggest that at least 25 cm H₂O is required45 75 this is significantly higher than the levels in general use. Some authors describe the routine placement of nasogastric tubes to prevent gastric distension,82 but this is probably unnecessary and can lead to excessive leaks.
Non-invasive ventilatory systems are, generally, quite tolerant of leaks but mouth leaks with nasal masks can lead to therapeutic failure. Oral loss of pressure with nasal ventilation may be prevented by the soft palate being pressed against the tongue to give a seal. When this is insufficient a chin strap may be applied or changing to a facemask may be indicated.

Case reports exist of other complications of non-invasive ventilation. A variety of arrhythmias (bradycardia, ventricular tachycardia, and ventricular standstill) have been reported during CPAP but were all probably related to underlying myocardial infarction. Pneumothorax is reported to have complicated treatment of \textit{P. carinii} pneumonia, but these patients are at high risk of this when ventilated by traditional means. A neonate is also reported to have suffered pulmonary venous air embolism while undergoing BiPAP treatment. These cases serve as an important reminder of the potential for barotrauma with any form of positive pressure ventilation. Pneumocephalus has been described in one patient receiving CPAP after weaning from traditional ventilation who had an unrecognised base of skull fracture as a result of a motor vehicle accident. One case of bilateral tympanic rupture and otorrhagia is reported in an agitated patient coughing against CPAP. Subconjunctival emphysema and corneal abrasions have also been reported; a well fitting mask significantly reduces the risk of both of these.

**Conclusions**

Non-invasive ventilation, CPAP and BiPAP, appears to be an effective additional to standard treatment for acute exacerbations of obstructive airways diseases and pulmonary oedema. It seems to be a safe, readily applied modality that decreases the need for endotracheal intubation, speeds recovery, and may shorten hospital length of stay.

Published experience, in the form of large randomised controlled trials, is remarkably limited and uniform recommendations with respect to indications, contraindications, and the exact manner in which non-invasive ventilation should be applied are lacking. Although there are some theoretical advantages of BiPAP over CPAP, there is no clinical evidence that one offers an advantage over the other in the treatment of acute respiratory failure in the emergency department. Further study is required to clarify these points.

Most of the evidence has been derived from intensive care settings. However, this therapy is extremely useful in an emergency department setting as a first line treatment for acute respiratory distress. Early intervention may avoid the risks and complications of endotracheal intubation and shorten or eliminate intensive care or high dependency admissions.

Clinicians should remain vigilant while using non-invasive ventilation as ongoing monitoring and reassessment remains the key to the successful application of this therapy. However, careful utilisation of non-invasive ventilation in appropriately selected patients will optimise the outcomes for patients with acute respiratory failure.

**Glossary of terms**

**Non-invasive ventilation**—application of artificial ventilation via nose or facemask (as opposed to invasive ventilation via an endotracheal tube). There are a number of types of non-invasive ventilation, described below, which are differentiated by the way in which pressure is applied to support ventilation.

- **Positive end expiratory pressure (PEEP)**—positive alveolar pressure at the end of expiration. May be intrinsic PEEP (iPEEP) due to dynamic hyperinflation (loss of lung compliance causes prolonged expiration, airway closure, and gas trapping in the alveoli) or externally applied or extrinsic PEEP (ePEEP) caused by CPAP or the EPAP component of BiPAP.

- **Continuous positive airway pressure (CPAP)**—a single level of positive pressure is applied continuously throughout the whole respiratory cycle.

- **Bilevel positive airway pressure (BiPAP)**—a system of ventilation in which two levels of airway pressure are applied: inspiratory positive airway pressure (IPAP) and inspiratory positive airway pressure (EPAP). The lower pressure, EPAP, is applied during expiration. When the patient makes an inspiratory effort the device senses a small drop in pressure that triggers a flow of gas at the higher IPAP.

- **Pressure support ventilation**—the difference between the inspiratory and expiratory airway pressures, that is, amount of extra “help” the patient is receiving during inspiration. There is no pressure support ventilation during CPAP. Pressure support ventilation can be given alone, without CPAP or PEEP, in which case end expiratory pressure is atmospheric.

- **Chronic obstructive airways disease (COAD)** also called chronic obstructive lung or pulmonary disease (COLD, COPD)—a condition in which there is chronic obstruction to airflow due to chronic bronchitis and/or emphysema. Adult asthma, caused by bronchial hyper-reactivity, is included in obstructive airways disease (OAD) group for the purposes of this review.

- **Acute pulmonary oedema**—an increase in pulmonary venous pressure, most commonly caused by left ventricular failure, causing an accumulation of liquid in the tissue and airways of the lungs.

I would like to thank Associate Professor Peter Cameron and Dr Dominica Zentner for their critical comments during manuscript preparation.

Conflict of interest: none.

Funding: none.

32 Pinsky MR, Summer WR. Cardiac augmentation by phasic expiratory pressure (PEEP) does not depress left ventricular function in patients with acute respiratory failure. Anesthesiology 1984;61:489–90.
35 Pinsky MR, Summer WR. Cardiac augmentation by phasic expiratory pressure (PEEP) does not depress left ventricular function in patients with acute respiratory failure. Anesthesiology 1984;61:489–90.
Non-invasive ventilation in the emergency department


